Infimer Beta vs. Earnings Per Share
| INFR-M Stock | 14.60 14.50 14,500% |
For Infimer profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Infimer to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Infimer utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Infimer's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Infimer over time as well as its relative position and ranking within its peers.
Infimer |
Infimer Earnings Per Share vs. Beta Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Infimer's current stock value. Our valuation model uses many indicators to compare Infimer value to that of its competitors to determine the firm's financial worth. Infimer is currently regarded as number one stock in beta category among its peers. It is rated below average in earnings per share category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Infimer by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Infimer's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Infimer Earnings Per Share vs. Beta
Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Infimer |
| = | 1.62 |
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Infimer |
| = | (0.59) X |
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
Infimer Earnings Per Share Comparison
Infimer is currently under evaluation in earnings per share category among its peers.
Beta Analysis
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Infimer will likely underperform.
Infimer Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Infimer. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Infimer position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Infimer's important profitability drivers and their relationship over time.
Use Infimer in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Infimer position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Infimer will appreciate offsetting losses from the drop in the long position's value.Infimer Pair Trading
Infimer Pair Trading Analysis
The ability to find closely correlated positions to Infimer could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Infimer when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Infimer - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Infimer to buy it.
The correlation of Infimer is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Infimer moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Infimer moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Infimer can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Infimer position
In addition to having Infimer in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cryptocurrency Thematic Idea Now
Cryptocurrency
Dynamically computed list of top cryptocurrencies sorted bymarket capitalization. The Cryptocurrency theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cryptocurrency Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Infimer Stock
To fully project Infimer's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Infimer at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Infimer's income statement, its balance sheet, and the statement of cash flows.